Half-Year 2022 Financial and Clinical Trials Update
Polivy (polatuzumab vedotin)
ADC targeting CD79b to treat B cell malignancies
Indication
Phase/study
# of patients
Design
Primary endpoint
Status
CT Identifier
1L DLBCL
Phase III
POLARIX
N=879
ARM A: Polivy plus R-CHP
ARM B: R-CHOP
☐
Progression-free survival
FPI Q4 2017
Recruitment completed Q2 2019
Study met primary endpoint Q3 2021
■ Data presented at ASH 2021
■Filed in EU, Japan and China Q4 2021
Published in NEJM 2022 Jan 27;386(4):351-363
Approved in EU Q2 2022
NCT03274492
In collaboration with Seagen Inc.
DLBCL-diffuse large B cell lymphoma; R-CHP-Rituxan, cyclophosphamide, hydroxydoxorubicin, prednisone; R-CHOP=Rituxan, cyclophosphamide, doxorubicin, vincristine, and prednisone; ASH-American Society of Hematology,
NEJM-New England Journal of Medicine
Roche
99
99
OncologyView entire presentation